Document is current
Any future updates will be listed below
-
Authors
Saab, Charles https://orcid.org/0000-0003-4233-8088
Mansour, Abbas Ali https://orcid.org/0000-0001-8083-6024
Rahmah, Abbas Mahdi https://orcid.org/0000-0003-0368-4383
Al-Attar, Delman Raoof https://orcid.org/0009-0004-7058-1573
Al-Rubay’e, Haidar Fadhil https://orcid.org/0000-0002-3912-8103
Alidrisi, Haider Ayad https://orcid.org/0000-0003-3132-1758
Nwayyir, Hussein Ali https://orcid.org/0000-0001-7926-3660
Khudhair, Mahmood Shakir https://orcid.org/0000-0001-8183-6683
Ahmed, Mazyar Jabbar https://orcid.org/0009-0009-0340-2519
Al-Ibrahimi, Salim Marzouq https://orcid.org/0009-0001-1397-0204
Mahwi, Taha Othman https://orcid.org/0000-0001-9477-8814
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 11 November 2025
Accepted: 6 March 2026
First Online: 15 April 2026
Declarations
:
: Charles Saab has participated in research, and has acted as a advisor and served as B2peaker for Amgen, Astra Zeneca, MSD, Novo Nordisk, Sanofi, Novartis, Genentech, Merck Serono, J&J, Pharmaline, Ei Lilli, BI, Chiesi, BPI, Hikma, Takeda, Sandoz, Algorithm, Pfizer. Abbas Ali Mansour has acted as a consultant/advisor and speaker for Novo Nordisk, Sanofi and Servier. Abbas Mahdi Rahmah has acted as a consultant/advisor and speaker for Novo Nordisk, Sanofi, Servier, Merck, Ajanta and AstraZeneca. Delman Raoof Al-Attar acted as a speaker for many international companies like Sanofi, Eli Lilly, Novo Nordisk, Merck, MSD, Boehringer Ingelheim and AstraZeneca. Haidar Fadhil Al-Rubay’e has acted as a consultant/advisor and speaker for Sanofi, Merck, Novo Nordis and AstraZeneca, Eli Lilly. He has also contributed to the Iraqi Consensus of Diabetes supported by Merck. Haider Ayad Alidrisi has acted as a consultant/advisor for Sanofi,Merck and Novo Nordisk. Also, act as an active speaker for Boehringer Ingelheim, Sanofi, AstraZeneca, Merck, Novo Nordisk, Eli Lilly. Hussein Ali Nwayyir has acted as a speaker for Sanofi, Novo Nordisk and AstraZeneca, and has served as a consultant/advisor for Sanofi. He has also participated in writing the Iraqi oral diabetes mellitus treatment guideline in collaboration with Merck. Mahmood Shakir Khudhair has acted as a speaker for Hikma, AstraZeneca, Novo Nordisk, Sanofi, Merck and Boehringer Ingelheim, and has served as a consultant/advisor for Sanofi, AstraZeneca, Merck and Eli Lilly. Mazyar Jabbar Ahmed acted as a consultant/advisor and speaker for many international companies like Sanofi, Novo Nordisk, Merck, and AstraZeneca. Salim Marzouq Al-Ibrahimi has acted as a consultant/advisor for Sanofi in diabetes and dyslipidemia, has contributed to the Iraqi Diabetes Guideline Consensus supported by Merck, and has served as a speaker for Sanofi, Novo Nordisk, Eva Pharm and Boehringer Ingelheim. Taha Othman Mahwi has acted as a consultant/advisor and speaker for Sanofi,Merck, Novo Nordis and AstraZeneca, He has also contributed to the Iraqi Consensus of Diabetes supported by Merck. All authors have received an honorarium from Sanofi for the Sanofi advisory board and have not received any honorarium for the publication.
: This article is based on previously published studies and expert consensus discussions and does not include any new studies involving human participants or animals performed by the authors.
